Eur J Endocrinol 181(6):R211R234 Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
You will often hear this class referred to as the "gliptins," because most of the generics carry that suffix: sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina)
GLP-1RAs are currently available as twice-daily (exenatide), once-daily (liraglutide and lixisenatide), or once-weekly subcutaneous injections (semaglutide, dulaglutide, and exenatide extended-release) and as a once-daily tablet for oral administration (oral semaglutide) (Table 1) [37]
The medical director of the VCU Health Medical Weight Loss Program explains what these medications do to the body and why they might not be suited for everyone
Injecting into the same exact spot every week can cause lipohypertrophythickened, lumpy tissue that not only feels uncomfortable but can actually interfere with how well your medication is absorbed
This is why oral GLP-1 medications come with stricter administration requirements and may produce more variable outcomes